Revenue
2018
2019
2020
2021
2022
2023
2024
2025
JOHNSON & JOHNSON (JNJ)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B | $76.45B | $71.89B | — | — | — | — | — | — | — | — | — |
| Gross profit | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.50B | $54.49B | $51.01B | $50.10B | $48.54B | $51.59B | $48.97B | $45.57B | $44.67B | $42.80B | $43.45B | $45.24B | $43.34B |
| Research & development | $14.66B | $17.23B | $15.09B | $14.13B | $14.28B | $12.16B | $11.36B | $10.78B | $10.59B | $9.14B | $9.05B | $8.49B | $8.18B | $7.67B | $7.55B | $6.84B | $6.99B | $7.58B | $7.68B |
| Operating income | — | — | — | — | — | — | — | — | — | — | — | $21.59B | $16.41B | $14.96B | $13.77B | $17.70B | $16.58B | — | — |
| EBITDAderived | — | — | — | — | — | — | — | — | — | — | — | $25.48B | $20.52B | $18.62B | $16.92B | $20.64B | $19.36B | — | — |
| Net income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B | $1.30B | $16.54B | $15.41B | $16.32B | $13.83B | $10.85B | $9.67B | $13.33B | $12.27B | $12.95B | $10.58B |
| Basic EPSper diluted share | $11.13 | $5.84 | $13.88 | $6.83 | $7.93 | $5.59 | $5.72 | $5.70 | $0.48 | $6.04 | $5.56 | $5.80 | $4.92 | $3.94 | $3.54 | $4.85 | $4.45 | $4.62 | $3.67 |
| Diluted EPSper diluted share | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 | $5.48 | $5.70 | $4.81 | $3.86 | $3.49 | $4.78 | $4.40 | $4.57 | $3.63 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 11, 2026Form 4 | Wengel Kathryn EEVP, Chief TO and Risk Officer | SellCommon Stock | 10.0K | $241.15 | $2.41M | 114.3K |
| Feb 27, 2026Form 4 | Decker Robert JVP Corporate Controller | SellCommon Stock | 4.1K | $247.87 | $1.01M | 23.7K |
| Feb 20, 2026Form 4 | Schmid TimothyEVP, WW Chair, MedTech | SellCommon Stock | 1.3K | $245.66 | $324.8K | 25.4K |
| Feb 18, 2026Form 4 | Schmid TimothyEVP, WW Chair, MedTech | SellCommon Stock | 9.0K | $244.53 | $2.20M | 26.8K |
| Feb 18, 2026Form 4 | Schmid TimothyEVP, WW Chair, MedTech | SellCommon Stock | 13.6K | $244.20 | $3.33M | 26.8K |